Keith Regnante - 04 Nov 2023 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role: Chief Financial Officer
Signature: /s/ Keith Regnante
Issuer symbol: KROS
Transactions as of: 04 Nov 2023
Net transactions value: -$1,171,600
Form type: 4
Filing time: 08 Jan 2024, 16:43:46 UTC
Previous filing: 12 Jun 2023
Next filing: 24 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KROS	Common Stock	Options Exercise	$640,000	+40,000		$16.00	40,000	04 Nov 2023	Direct	F1
transaction	KROS	Common Stock	Sale	$1,811,600	-40,000	-100%	$45.29	0	04 Nov 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KROS	Employee Stock Option (right to buy)	Options Exercise	$0	-40,000	-43%	$0.000000	53,622	04 Jan 2024	Common Stock	40,000	$16.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023.
F2	One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.